Entrada Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $19,570 | $94,694 | $59,120 | $41,848 |
Gross Profit | 18,670 | 93,794 | 58,186 | 41,112 |
EBITDA | -21,658 | 53,423 | 22,047 | 5,641 |
EBIT | -22,595 | 52,523 | 21,113 | 4,905 |
Net Income | -14,032 | 55,031 | 23,496 | -9,544 |
Net Change In Cash | 19,570 | 94,694 | 59,120 | 41,848 |
Free Cash Flow | -24,905 | 38,787 | -26,357 | -4,989 |
Cash | 78,049 | 185,253 | 68,436 | 67,602 |
Basic Shares | 40,629 | 35,507 | 34,790 | 33,368 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $129,013 | $25,260 | $0 | $0 |
Gross Profit | 29,129 | -1,895 | -1,117 | -326 |
EBITDA | -321 | -95,353 | -50,010 | -26,341 |
EBIT | -3,162 | -97,248 | -51,127 | -26,667 |
Net Income | -6,685 | -87,457 | -50,072 | -26,379 |
Net Change In Cash | 129,013 | 25,260 | 0 | 0 |
Cost of Revenue | 252,019 | |||
Free Cash Flow | 134,189 | -96,673 | -55,442 | -27,895 |
Cash | 67,602 | 45,157 | 291,064 | 39,045 |
Basic Shares | 33,050 | 31,293 | 31,224 | 31,248 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.35 |
2024-06-30 | $1.54 |
2024-03-31 | $0.68 |
2023-12-31 | -$0.29 |
